journal
https://read.qxmd.com/read/38606685/trends-in-antibiotic-prescriptions-in-hidradenitis-suppurativa-from-2015-2021
#1
JOURNAL ARTICLE
Mikael Horissian, Christen Samaan, Austin Cohrs, Joslyn Kirby
No abstract text is available yet for this article.
April 12, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38606681/a-qualitative-study-of-the-psychological-morbidity-in-paediatric-survivors-of-stevens-johnson-syndrome-and-toxic-epidermal-necrolysis
#2
JOURNAL ARTICLE
Chris Phillips, Emily Russell, Abigail McNiven, Tess McPherson
No abstract text is available yet for this article.
April 12, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38596857/real-world-study-on-the-use-of-pegylated-interferon-alpha-2a-for-treatment-of-mycosis-fungoides-s%C3%A3-zary-syndrome-using-time-to-next-treatment-as-a-measure-of-clinical-benefit-an-eortc-cltg-study
#3
JOURNAL ARTICLE
Keila Mitsunaga, Martine Bagot, Caroline Ram-Wolff, Emmanuella Guenova, Christina von Gugelberg, Emmilia Hodak, Iris Amitay-Laish, Evangelia Papadavid, Constanze Jonak, Stefanie Porkert, Julia Scarisbrick, Rona Applewaite, Marie Beylot-Barry, Jan Nicolay, Pietro Quaglino, José Antonio Sanches, Jade Cury-Martins, David Lora-Pablos, Pablo Ortiz
INTRODUCTION: Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon alpha (IFN-α, subtypes 2a and 2b) has been used for MF/SS since 1984, however its production was recently stopped and so the recombinant pegylated (PEG) form of IFN α-2a remains as single IFN alternative treatment, even though not approved for MF/SS. OBJECTIVE: To assess effectiveness and safety of PEG IFN α-2a in monotherapy and in combination with other treatments using time to next treatment (TTNT) as a measure of clinical therapeutic benefit in real world setting...
April 10, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38595050/paediatric-onset-lymphomatoid-papulosis-results-of-a-multicentre-retrospective-cohort-study-on-behalf-of-the-eortc-cutaneous-lymphoma-tumours-group-cltg
#4
JOURNAL ARTICLE
Maël Blanchard, Marie-Anne Morren, Anne-Marie Busschots, Esther Hauben, Silvia Alberti-Violetti, Emilio Berti, Gianluca Avallone, Gianluca Tavoletti, Michele Panzone, Pietro Quaglino, Cristiana Colonna, Rutger C Melchers, Maarten H Vermeer, Robert Gniadecki, Christina Mitteldorf, Janika Gosmann, Rudolf Stadler, Constanze Jonak, Meital Oren-Shabtai, Emmilia Hodak, Rivka Friedland, Emily Gordon, Larisa J Geskin, Julia J Scarisbrick, Fatima Mayo Martínez, Lucero Noguera Morel, Kevin Pehr, Boyko Amarov, Mohamed Faouzi, Jan P Nicolay, Werner Kempf, Gabriela Blanchard, Emmanuella Guenova
BACKGROUND: Lymphomatoid Papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population is scarce. OBJECTIVES: To characterize epidemiological, clinical, histopathological, and prognostic features of paediatric LyP. METHODS: This was a retrospective, multicentre international cohort study including 87 cases of children and adolescents with LyP diagnosed between 1998 and 2022...
April 10, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38593243/antifungal-resistant-trichophyton-indotineae-transmission-is-occurring-outside-the-previously-identified-endemic-areas-are-we-prepared
#5
JOURNAL ARTICLE
Alireza Abdolrasouli, Roderick J Hay
No abstract text is available yet for this article.
April 9, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38593196/evaluating-the-clinical-utility-of-the-atopic-dermatitis-control-tool-measurement-properties-and-agreement-between-patients-responses-and-clinicians-impressions-of-atopic-dermatitis-control
#6
JOURNAL ARTICLE
Eric L Simpson, Laurent Eckert, Abhijit Gadkari, T Michelle Brown, Peter A Lio, Benjamin Lockshin, Lauren Nelson, Sheri E Fehnel, Puneet Mahajan, Jingdong Chao, Michaela Nygårdas, Isabelle Guillemin
No abstract text is available yet for this article.
April 9, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38593191/cryosim-1-a-cool-solution-for-acute-and-chronic-itch
#7
EDITORIAL
Darya Pavlenko, Tasuku Akiyama
No abstract text is available yet for this article.
April 9, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38591490/midfacial-toddler-excoriation-syndrome-mites-case-series-diagnostic-criteria-and-evidence-for-a-pathogenic-mechanism
#8
JOURNAL ARTICLE
Nivedita Sarveswaran, Yunisa Pamela, Akhila A N Reddy, Akash P Mustari, Anchala Parthasarathi, Anthony J Mancini, Anuradha Bishnoi, Arun C Inamadar, Bayanne Olabi, Fiona Browne, Gargi N Deshmukh, Kenneth McWilliam, Keshavamurthy Vinay, Sahana Srinivas, Samantha Ibbs, Sivakumar Natarajan, Vadlamudi R Rao, Vijay Zawar, Vykuntaraju K Gowda, Samiha S Shaikh, Celia Moss, Christopher G Woods, Ichrak Drissi
BACKGROUND: PRDM12 polyalanine tract expansions cause two different disorders; Midfacial Toddler Excoriation Syndrome (MiTES) - itch with normal pain sensation associated with homozygous 18 alanines (18A), and congenital insensitivity to pain (CIP) with normal itch with homozygous 19A. Knowledge of the phenotype, genotype, and disease mechanism of MiTES is incomplete. Why PRDM12 18A versus 19A can cause almost opposite phenotypes is unknown; no other poly-alanine or poly-glutamine tract expansion disease causes two such disparate phenotypes...
April 9, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38590102/using-artificial-intelligence-based-technologies-to-support-the-diagnosis-and-early-detection-of-melanoma-in-primary-care
#9
EDITORIAL
Owain T Jones, Rubeta N Matin, Fiona M Walter
No abstract text is available yet for this article.
April 9, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38584369/glmn-variants-cause-skin-hyperpigmentation-a-promising-potential-therapeutic-target
#10
EDITORIAL
Qiaoyu Cao, Ming Li
No abstract text is available yet for this article.
April 8, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38584365/debunking-the-myth-that-all-emollients-are-equal-opens-the-door-for-future-ad-prevention-studies
#11
JOURNAL ARTICLE
Simon G Danby
No abstract text is available yet for this article.
April 8, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38584300/a-cross-sectional-study-of-erythromelalgia-in-patients-with-pachyonychia-congenita
#12
JOURNAL ARTICLE
Rebecca L McCarthy, Janice Schwartz, Jaimie Oldham, Christine Bodemer, Celine Greco, Alain Hovnanian, C David Hansen, Edel A O'Toole
No abstract text is available yet for this article.
April 8, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38581445/a-deep-learning-approach-for-direct-immunofluorescence-pattern-recognition-of-autoimmune-bullous-diseases
#13
JOURNAL ARTICLE
Niccolò Capurro, Vito Paolo Pastore, Larbi Touijer, Francesca Odone, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi
BACKGROUND: Artificial intelligence (AI) is reshaping healthcare, using machine and deep learning to enhance disease management. Dermatology has seen improved diagnostics, particularly in skin cancer detection, through the integration of AI. However, the potential of AI in automating immunofluorescence imaging for autoimmune bullous skin diseases remains untapped. While direct immunofluorescence (DIF) supports diagnosis, its manual interpretation can hinder efficiency. The use of deep learning to automatically classify DIF patterns, including the Intercellular Pattern (ICP) and the Linear Pattern (LP), holds promise for improving the diagnosis of autoimmune bullous skin diseases...
April 6, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38576352/cutaneous-t-cell-lymphoma-care-across-europe-insights-from-the-horizon-project
#14
JOURNAL ARTICLE
Gabriele Roccuzzo, Joana Calvão, Gabor Dobos, Erika Morsia, Pablo Mozas, Elizabeth Peterknecht, Anne M R Schrader, Francesca Zottarelli, Martine Bagot, Rudolf Stadler, Maarten Vermeer, Pietro Quaglino, Julia Scarisbrick
No abstract text is available yet for this article.
April 5, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38576350/proof-of-concept-study-exploring-the-effect-of-spesolimab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa-a-randomized-double-blind-placebo-controlled-clinical-trial
#15
JOURNAL ARTICLE
Afsaneh Alavi, Errol Prens, Alexa B Kimball, John W Frew, James G Krueger, Sutirtha Mukhopadhyay, Heli Gao, Usha Ranganathan, Nathalie B Ivanoff, Ana C Hernandez Daly, Christos C Zouboulis
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies. OBJECTIVE: To explore the effects of spesolimab treatment in patients with HS. METHODS: This randomized, double-blind, placebo-controlled, proof-of-clinical-concept study was conducted at 25 centers across 12 countries from May 3, 2021, to April 21, 2022...
April 5, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38564268/incidence-of-anxiety-disorder-among-adults-with-hidradenitis-suppurativa
#16
JOURNAL ARTICLE
Erica Cohn, Gabriela Palma, Nicole Mastacouris, Andrew Strunk, Amit Garg
BACKGROUND: There is limited data on risk of new-onset anxiety disorders in hidradenitis suppurativa (HS) patients. OBJECTIVES: To compare the risk of new-onset anxiety disorder in patients with HS and controls, and to describe risk factors for development of anxiety among HS patients. METHODS: Retrospective cohort analysis of a US electronic health records database between 2011-2020. Adults newly diagnosed with HS at a dermatology or primary care visit and controls were included...
April 2, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38561894/combined-rituximab-and-belimumab-to-treat-recalcitrant-epidermolysis-bullosa-aquisita-associated-with-systemic-lupus-erythematosus
#17
JOURNAL ARTICLE
Thomas J Tull, Emma C Benton, Kristina Semkova, Natalie A Watson, John B Mee, Begona Lopez, Jane Setterfield, Barbara Carey, Sajjad Ajmad, Scott J Robbie, Richard W Groves, Giovanni Sanna, David P D'Cruz
No abstract text is available yet for this article.
April 2, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38544457/sensitive-and-specific-assay-for-the-serological-diagnosis-of-anti-p200-pemphigoid-based-on-the-recombinant-laminin-%C3%AE-4-subunit
#18
JOURNAL ARTICLE
Stephanie Goletz, Christian Probst, Lars Komorowski, Christiane Radzimski, Swantje Mindorf, Maike M Holtsche, Manuela Pigors, Nina van Beek, Detlef Zillikens, Wolfgang Schlumberger, Enno Schmidt
No abstract text is available yet for this article.
March 28, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38534203/effect-of-smoking-cessation-on-psoriasis-vulgaris-palmoplantar-pustulosis-and-generalized-pustular-psoriasis
#19
JOURNAL ARTICLE
Seong Rae Kim, Young-Geun Choi, Seong Jin Jo
BACKGROUND: Smoking is a known risk factor for psoriasis; however, the impact of smoking cessation on psoriasis has seldom been evaluated. OBJECTIVES: We aimed to examine the effects of smoking cessation on the development of psoriasis vulgaris (PsV), palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP). METHODS: Using the Korean National Health Insurance Service database, we retrospectively compiled a cohort of 5,784,973 participants without psoriasis, analysed their changes in smoking status from 2004 to 2007 and followed up new cases of psoriasis until 2021...
March 27, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38534198/burden-of-disease-and-treatment-patterns-amongst-patients-with-vitiligo-findings-from-a-national-longitudinal-retrospective-study-in-the-united-kingdom
#20
JOURNAL ARTICLE
Viktoria Eleftheriadou, Carine Delattre, Shala Chetty-Mhlanga, Christopher Lee, Laura Girardat-Rotar, Iftekhar Khan, Amit Mathew, Andrew R Thompson
This retrospective study, using UK Clinical Practice Research Datalink and Hospital Episode Statistics databases, analysed 17,239 incident patients with vitiligo. Mean incidence of vitiligo was 0.16 (2010-2021) per 1000 person-years (range: 0.10 [2010-COVID] to 0.19 [2013/2018]); prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%), and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time were most commonly depression and/or anxiety (24...
March 27, 2024: British Journal of Dermatology
journal
journal
20056
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.